{
  "slug": "nadh",
  "name": "NADH (Reduced Nicotinamide Adenine Dinucleotide)",
  "alternate_names": [
    "Reduced NAD",
    "ENADA (stabilized NADH)",
    "Coenzyme 1"
  ],
  "mechanism": [
    "Mitochondrial Complex I electron donor",
    "Tetrahydrobiopterin recycling",
    "Dopamine biosynthesis support",
    "Cellular ATP production"
  ],
  "target": [
    "Mitochondrial electron transport chain",
    "Dopamine biosynthesis pathway",
    "Cellular bioenergetics"
  ],
  "use_case": [
    "chronic fatigue syndrome (research context)",
    "jet-lag cognition",
    "cellular energy support"
  ],
  "body_system": [
    "MITO",
    "CNS",
    "IMMUNE"
  ],
  "evidence_tier": "B",
  "evidence_anchor_pmid_count": 54,
  "evidence_long_form_url": "https://asxan.ai/blog/reduced-nadh-vs-nmnh-evidence/",
  "dosage_range": "5-20 mg/day (Forsyth 1999 CFS RCT 10 mg/day; Birkmayer 2002 jet-lag 5 mg)",
  "safety_notes": "Generally well tolerated; long-term human safety beyond 6 months limited; NADH formulation stability requires enteric coating",
  "regulatory": {
    "fda": "DSHEA dietary supplement (since 1996)",
    "efsa": "Novel Food classification (case-by-case)",
    "anvisa": "RDC 243/2018 dietary supplement framework"
  },
  "ingredient_hub_url": "https://asxan.ai/ingredients/nadh/",
  "related_goal_slugs": [
    "longevity-stack",
    "cognitive-support",
    "athletic-performance",
    "heart-health"
  ],
  "related_lifestyle_slugs": [
    "senior-60-plus",
    "high-stress",
    "athletic-performance"
  ],
  "last_evidence_review": "2026-05-26",
  "schema_version": "nc-public-v0.1"
}